Catalyst Biosciences Inc (CBIO)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

611 GATEWAY BLVD., SUITE 710 SOUTH SAN FRANCISCO, CA 94080

Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of drugs for the treatment of multiple diseases and disorders of the central nervous system. As of December 31, 2006, the company had four clinical-stage product candidates and three preclinical product candidates in its product portfolio. Its product candidates are in development as treatments for target indications in three therapeutic areas: cognitive impairment, depression and anxiety, and pain. The company principally offers Inversine, which is approved for marketing for the management of moderately severe to severe essential hypertension, a high blood pressure disorder. Its product candidates include TC-1734, a Phase II clinical trial completed product for the treatment of Alzheimer's disease, cognitive deficits in schizophrenia, and other conditions characterized by cognitive impairment, such as attention deficit hyperactivity disorder, age associated memory impairment, and mild cognitive impairment. Targacept's product candidates also include TC-2696 for acute post-operative pain; mecamylamine hydrochloride, the active ingredient in Inversine; and TC-5214, one of the enantiomers of mecamylamine hydrochloride; TC-2216, a phase I product for depression and anxiety disorders; and TC-5619 for various conditions, such as schizophrenia, cognitive impairment, and inflammation. The company has a collaborative research and license agreement with AstraZeneca AB for development and commercialization of TC-1734 to treat Alzheimer's disease, cognitive deficits in schizophrenia, and other cognitive disorders.

Data as of 2021-05-08 10:40:46 -0400
Market Cap141.387 Million Shares Outstanding31.35 Million Avg 30-day Volume349.542 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.87236 52-week High/Low8.22 / 4.05 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from CBIO instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 2 0.0% 2 (0.12%) 2 (0.12%) 0.0%
Funds Holding: 82 80 2.5% 31 (1.86%) 33 (2.05%) -6.06%
13F shares: 14.367 Million 14.095 Million 1.93% 8.991 Million 10.119 Million -11.15%
% Ownership 65.0159 63.7852 1.93% 40.687 45.7909 -11.15%
New Positions: 18 9 100.0% 6 4 50.0%
Increased Positions 31 33 -6.06% 10 14 -28.57%
Closed Positions 15 9 66.67% 7 5 40.0%
Reduced Positions 18 20 -10.0% 12 9 33.33%
Total Calls 293.745 Thousand 64.972 Thousand 352.11% 257.8 Thousand 0
Total Puts 12.1 Thousand 1 Thousand 1110.0% 12.1 Thousand 0
PUT/CALL Ratio 0.04 0.02 100.0% 0.05 150.0%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CBIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CBIO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

5 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

USMAN NASSIM PRESIDENT & CEO

  • Officer
  • Director
286,581 2021-04-05 5

DESOUZA ERROL B

  • Director
22,807 2021-04-01 5

LAWLOR AUGUSTINE

  • Director
37,407 2021-04-01 5

HUNT ANDREA

  • Director
15,997 2021-04-01 5

WILLIAMS EDDIE

  • Director
18,102 2021-04-01 5

LING GEOFFREY M.D.

  • Director
13,364 2021-04-01 5

LEVY HOWARD CHIEF MEDICAL OFFICER

  • Officer
23,390 2021-02-09 4

MUSIL CLINTON CHIEF FINANCIAL OFFICER

  • Officer
54,000 2021-02-08 4

TETLOW SHARON

  • Director
3,635 2020-07-01 2

RICHARD JOHN P

  • Director
3,716 2020-03-13 0

CAI VERONICA CONTROLLER

  • Officer
7,353 2020-03-13 0

PAYNE FLETCHER CHIEF FINANCIAL OFFICER

  • Officer
0 2019-08-30 0

HILL STEPHEN A

  • Director
1,190 2018-09-06 0

JFL CAPITAL MANAGEMENT, LLC

  • 5% OWNER
0 2018-07-27 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD PARTNERS, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
5,661,484 2018-03-06 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
1,113,222 2018-03-06 0

SELICK HAROLD E

  • Director
0 2018-01-16 0

MADISON EDWIN CHIEF SCIENTIFIC OFFICER

  • Officer
0 2015-10-22 0

HIMAWAN JEFF

  • Director
0 2015-08-20 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INC/IL

LAMPERT MARK N

BVF INVESTMENTS LLC

INVESTMENT 10 LLC

  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
No longer subject to file 2015-08-20 0

ESSEX WOODLANDS HEALTH VENTURES VIII, L.L.C.

ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.

  • 10% Owner
1,179,352 2015-08-20 0

BLIXT CHARLES A

  • Director
No longer subject to file 2015-08-14 0

BROWN JULIA R

  • Director
No longer subject to file 2015-08-14 0

DUNTON ALAN W

  • Director
No longer subject to file 2015-08-14 0

HODGES MAURI K TREASURER, CFO

  • Officer
No longer subject to file 2015-08-14 0

ROCK PATRICK C. SECRETARY, GC

  • Officer
No longer subject to file 2015-08-14 0

MUSSO ALAN A SVP, FIN+ADMIN, CFO & TREAS

  • Officer
57,799 2014-10-17 0

TOLER STEVEN M. VP, CLIN PHARM SCIENCES

  • Officer
46,000 2014-10-17 0

HOSFORD DAVID A. VP, CLIN DEV & REG AFFAIRS

  • Officer
0 2014-01-23 0

BARRIS PETER J

  • 10% Owner
4,563,512 2013-12-05 0

SANDELL SCOTT D

  • 10% Owner
4,563,512 2013-12-05 0

BARRETT M JAMES

  • 10% Owner
4,563,512 2013-12-03 0

SKALETSKY MARK B

  • Director
0 2013-06-07 0

BRENNAN JEFFREY P SVP, BUS. AND COMM. DEV. & CBO

  • Officer
0 2013-01-17 0

BENCHERIF MEROUANE SVP AND SENIOR SCIEN FELLOW

  • Officer
0 2013-01-17 0

ZORN PETER A SVP, LGL AFFRS, GC & SECRETARY

  • Officer
0 2013-01-17 0

HICKS KAREN A VP, HUMAN RESOURCES

  • Officer
0 2013-01-17 0

INVESTMENT 10 LLC

  • SEE EXPLANATION OF RESPONSES
6,171,669 2013-01-01 0

KRAMLICH C RICHARD

  • 10% Owner
4,568,845 2012-11-19 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INC/IL

LAMPERT MARK N

BVF INVESTMENTS LLC

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES SEE EXPLANATION OF RESPONSES
8,616,634 2012-11-14 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
5,710,899 2012-11-07 0

BURRILL STEVEN

  • Director
4,333 2012-07-31 0

SNYDERMAN RALPH

  • Director
0 2012-06-07 0

DEBETHIZY J DONALD PRESIDENT AND CEO

  • Officer
  • Director
0 2012-05-04 0

CALDWELL WILLIAM S SVP - DRUG DISCOVERY AND DEV.

  • Officer
9,235 2011-09-20 0

DUNBAR GEOFFREY C SVP, CLIN. DEV. & REG. AFFAIRS

  • Officer
0 2011-03-29 0

PERRY MARK W

  • 10% Owner
4,565,512 2008-01-17 0

NEWHALL CHARLES W III

  • 10% Owner
4,565,512 2008-01-17 0

TRAINOR III EUGENE A

  • 10% Owner
4,563,512 2008-01-17 0

NEA PARTNERS 10 L P

  • 10% Owner
4,563,512 2008-01-17 0

NEW ENTERPRISE ASSOCIATES 10 L P

  • 10% Owner
4,563,512 2008-01-17 0

JONES ELAINE V

  • FORMER DIRECTOR AS OF 6/13/07
No longer subject to file 2007-11-29 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

USMAN NASSIM - Director - Officer PRESIDENT & CEO

2021-04-07 10:55:14 -0400 2021-04-05 M 5,000 $4.63 a 17,174 direct 2.1739 -1.1858 2.1739 2 -1.1858 5

USMAN NASSIM - Director - Officer PRESIDENT & CEO

2021-04-07 10:55:14 -0400 2021-04-05 M 5,000 d 259,783 direct

LAWLOR AUGUSTINE - Director

2021-04-05 13:38:43 -0400 2021-04-01 A 4,761 a 13,192 direct -2.1195 -2.6975 0.0 1 -2.6975 6

DESOUZA ERROL B - Director

2021-04-05 13:37:14 -0400 2021-04-01 A 2,926 a 22,807 direct -2.1195 -2.6975 0.0 1 -2.6975 6

LING GEOFFREY M.D. - Director

2021-04-05 13:39:57 -0400 2021-04-01 A 2,331 a 13,364 direct -2.1195 -2.6975 0.0 1 -2.6975 6

HUNT ANDREA - Director

2021-04-05 13:37:56 -0400 2021-04-01 A 2,480 a 15,997 direct -2.1195 -2.6975 0.0 1 -2.6975 6

WILLIAMS EDDIE - Director

2021-04-05 13:41:05 -0400 2021-04-01 A 1,215 a 18,102 direct -2.1195 -2.6975 0.0 1 -2.6975 6

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CATALYST BIOSCIENCES INC CBIO 2021-05-14 22:15:03 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 21:45:03 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 21:15:03 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 20:45:03 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 20:15:04 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 19:45:02 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 19:15:03 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 18:45:03 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 18:15:03 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 17:45:03 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 17:15:03 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 16:45:03 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 16:15:03 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 15:45:03 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 15:15:02 UTC -1.165 1.215 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 14:45:04 UTC -1.1548 1.2048 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 14:15:03 UTC -1.1548 1.2048 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 13:45:03 UTC -1.1548 1.2048 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 13:15:03 UTC -1.1548 1.2048 1700000
CATALYST BIOSCIENCES INC CBIO 2021-05-14 12:45:03 UTC -1.1548 1.2048 1700000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments